Goserelin Acetate 10.8 mg Plus Iron Versus Iron Monotherapy Prior to Surgery in Premenopausal Women with Iron-Deficiency Anemia Due to Uterine Leiomyomas: Results from a Phase III, Randomized, Multicenter, Double-Blind, Controlled Trial

Clinical Therapeutics

Volumn 29, Issue 8, 2007, Pages 1682-1691

  Muneyyirci Delale, Ozgul ^a   Richard Davis, Gloria ^b   Morris, Tom ^c   Armstrong, Jon ^c  

^a State University   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

fibroids; goserelin; hemoglobin; leiomyomas; premenopausal; uterus

Indexed keywords

FERROUS SULFATE; GOSERELIN; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; ASTHENIA; ASTHMA; BLEEDING; BLOOD TRANSFUSION; BONE DENSITOMETRY; BONE DISEASE; CELLULITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERANCE; FEMALE; GASTRITIS; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HEMOPERITONEUM; HOT FLUSH; HUMAN; HYSTERECTOMY; INSOMNIA; INTESTINE OBSTRUCTION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MENOPAUSE; MENORRHAGIA; MULTICENTER STUDY; MYOMECTOMY; PATIENT COMPLIANCE; PELVIS PAIN SYNDROME; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; URINARY TRACT INFECTION; UTERUS BLEEDING; UTERUS MYOMA; VAGINA BLEEDING; VULVOVAGINITIS;

ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; ANTINEOPLASTIC AGENTS, HORMONAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FERROUS COMPOUNDS; GOSERELIN; GYNECOLOGIC SURGICAL PROCEDURES; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; LEIOMYOMA; NORTH AMERICA; PREMEDICATION; PREMENOPAUSE; TIME FACTORS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 34848833880     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.08.024     Document Type: Article

References (17)

1. Bajekal N., and Li T. Fibroids, infertilityand pregnancywastage. Hum Reprod Update 6 (2000) 614-620
2. Buttram Jr. V., and Reiter R. Uterine leiomyomata: Etiology, symptomatology, and management. Fertil Steril 36 (1981) 433-445
3. Walker C., and Stewart E. Uterine fibroids: The elephant in the room. Science 308 (2005) 1589-1592
4. Marshall L., Spiegelman D., Barbieri R., et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90 (1997) 967-973
5. Chapman L., and Magos A. Surgical and radiological management of uterine fibroids in the UK. CurrOpin Obstet Gynecol 18 (2006) 394-401
6. Smart O., Hindley J., Regan L., and Gedroyc W. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol 108 (2006) 49-54
7. Cohen B., and Gibor Y. Anemia and menstrual blood loss. Obstet Gynecol Surv 35 (1980) 597-618
8. Lethaby A., Vollenhoven B., and Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: A systematic review. BIOG 109 (2002) 1097-1108
9. Benagiano G., Kivinen S., Fadini R., et al. Zoladex (goserelin acetate) and the anemic patient: Results of a multicenter fibroid study. Fertil Steril 66 (1996) 223-229
10. Candiani G., Vercellini P., Fedele L., et al. Use ofgoserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand 69 (1990) 413-415
11. Lumsden M., West C., Thomas E., et al. Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. Br J Obstet Gynaecol 101 (1994) 438-442
12. World Medical Association. Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Ethical principles for medical research involving human subjects (2000)
13. Moher D., Schulz K., Altman D., and CONSORT Group. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 (2001) 1191-1194
14. Sonnenberg A. Bonferroni-Holm sequential test procedure [in German]. ZGastroenterol 23 (1985) 703-704
15. Heidenreich A., Aus G., Abbou C., et al. European Association of Urology Guidelines on Prostate Cancer (2007). http://www.uroweb.org/fileadmin/user_upload/Guidelines/O7_Prostate_Cancer_2OO7.pdf Accessed June 7, 2007
16. Smith M. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 20 (2003) 175-183
17. Smith M., McGovern F., Zietman A., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Meal 345 (2001) 948-955